Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822351 · ClinicalTrials.gov registry record · Phase 2
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT03822351 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 189 participants.
The verdict
NCT03822351, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.
Interventions
- DRUG Durvalumab
- DRUG Durvalumab + Oleclumab
- DRUG Durvalumab + Monalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2023-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03822351
The ClinicalTrials.gov registry entry for NCT03822351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT03822351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03822351 about?
NCT03822351 is a clinical study titled "Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC". The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable,...
What is the current status of trial NCT03822351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2018-12-19. Estimated completion is 2023-07-18.
What interventions are being tested in trial NCT03822351?
The interventions under investigation include: Durvalumab (DRUG), Durvalumab + Oleclumab (DRUG), Durvalumab + Monalizumab (DRUG).
Who is sponsoring clinical trial NCT03822351?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.